Medmira Inc (TSE:MIR) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Medmira Inc. reports a significant corporate milestone with the US FDA 510(k) clearance for its Reveal G4 Rapid HIV-1/2 antibody test, set to bolster its U.S. market share and revenues. The company also completed supporting studies for Health Canada and expanded its Commercialisation Department, aiming to strengthen its North American presence. Despite these advancements, Medmira experienced a net loss of $590,789 this quarter, with a slight increase in working capital deficit.
For further insights into TSE:MIR stock, check out TipRanks’ Stock Analysis page.